Hutchison MediPharma gets $12.5m support from Mitsui
Mitsui has invested $12.5m in cash in return for new convertible Preference Shares giving Mitsui 12.2% of the enlarged share capital of Hutchison MediPharma. Mitsui Global Investment Department
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.
The certification covers single-dose and multiple-dose toxicology studies in both rodents and non-rodents, GeneTox studies (Ames, micronucleus, and chromosome aberration), and toxicokinetic studies. According to WuXi PharmaTech, the